Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs GSK plc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52, while GSK plc trades at $51.45 (market cap $101.55B). The key difference: GSK plc pays a 3.5% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and GSK plc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| BIL | GSK | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $61.18 |
52-Week Low | $91.27 | $36.20 |
Market Cap | — | $101.55B |
Enterprise Value | — | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.50 with no recent price movement. Technical indicators show a bearish trend, with moving averages signaling sell pressure and oscillators neutral. The ETF maintains consistent dividend payments of $0.27 per share. Market sentiment is influenced by Federal Reserve rate hike speculation and competition among cash ETFs, as noted in recent financial news.
The outlook for BIL hinges on interest rate trends, with potential upside if the Fed hikes rates, boosting short-term Treasury yields. Risks include prolonged low-rate environments and investor shifts to higher-yielding alternatives. Current technical weakness suggests caution, but the ETF's stability and dividends offer defensive appeal in volatile markets.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
